lamivudine has been researched along with Asymptomatic Conditions in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coffin, CS; Gill, MJ; Michalak, TI; Mulrooney-Cousins, PM; Nishikawa, S; Osiowy, C; van der Meer, F; van Marle, G | 1 |
| Arcaini, L; Bruno, R; Lucioni, M; Merli, M; Paulli, M; Rattotti, S; Riboni, R; Vercelli, A | 1 |
2 other study(ies) available for lamivudine and Asymptomatic Conditions
| Article | Year |
|---|---|
Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
Topics: Adult; Anti-HIV Agents; Asymptomatic Diseases; Base Sequence; DNA, Viral; Female; Gene Products, pol; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; North America; Sequence Analysis, DNA; Viral Load | 2014 |
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection.
Topics: Antiviral Agents; Asymptomatic Diseases; Bone Marrow; Carrier State; Cell Transformation, Viral; Disease Progression; Female; Genes, bcl-2; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Lymphoma, B-Cell; Lymphoma, Follicular; Middle Aged; Neoplasm, Residual; Remission Induction; Splenic Neoplasms | 2011 |